Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2013 Jan 1;2(1):e22410.

Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity.

Author information

  • 1Institute of Molecular Immunology; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany ; Clinical Cooperation Group "Immune Monitoring"; Helmholtz Zentrum München; German Research Center for Environmental Health; Munich, Germany.

Abstract

The clinical use of lymphocytes engineered to express high affinity T-cell receptors (TCRs) specific for two broadly expressed tumor-associated antigens is strongly limited by MHC-restricted fratricide of lymphocytes and TCR-mediated killing of hematopoietic stem cells. Specific clinical applications must therefore be conceived to bypass these limitations.

KEYWORDS:

MHC-restricted fratricide; TCR gene therapy; hematopoietic stem cell toxicity; hyluronan-mediated motility receptor; survivin

PMID:
23483031
[PubMed]
PMCID:
PMC3583918
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk